With over 20 years of experience in Pharma/Biotech, this candidate excels in leading global, regional, and country medical teams, demonstrating a strong track record in strategic planning and execution.
Expert in developing and implementing go-to-market strategies for biotech products, including oncology and rare diseases, with a focus on EU market entry and product launches. Very recent experience with radiopharmaceuticals (investigational)
Proven leader in strategic planning and cross-functional collaboration, effectively aligning R&D, Commercial, and Market Access teams to achieve strategic objectives and drive successful product launches.
Fluent in French, English, and German, this candidate is adept at influencing stakeholders and leading diverse international teams to achieve business goals.
)
)
Overview
- Availability
- Asap, full-time, remote & on-site
- Qualification
- Medical Doctor, MBA
- Language Skills
- French (Native), English (Fluent), German (Fluent)
- Relevant Expertise
- EU Market Entry, Global Medical Affairs, Strategic Planning, Product Launch, Due Diligence, Oncology, Rare Diseases, Radio Pharmacy, Biotech, Big Pharma
Key-Facts
Extract from previous activities
Interim VP Head Medical Affairs EMEA
Planned the build-up of a regional and country medical organization in Europe (28 FTEs), including medical infrastructure (Med Info, CRM, MLR)
Developed the medical strategy to support the first company launch of its main asset in Cardiology
Interim VP Global Medical Affairs
Designed and executed the Global Medical Affairs launch strategy for the Insomnia Franchise
Successfully drove global and supported local activities, which contributed to the successful launch of the first product in the US (2022) and EU (2022-23)
Interim Head Global Medical Communications
Planned and executed medical communication plans (publication, evidence generation and congress strategies) for seven therapeutic areas in support of regional launches in EU and US
Developed and led a team of 27 FTEs that coordinated across Medical Affairs, R&D, and Commercial the global commercial strategy
Interim Head Continuum of Access to Medicines
Implemented a sustainable Global Early Access Centre of Excellence across all TAs and Regions (EU/International)
Provided strategic leadership to the CAM team (10 FTEs) and oversight of CAM programs including Charitable Access, Named Patient Access (NPA), Compassionate use and post-trial Access
Interim Franchise Global Medical Lead
Developed Haematology Rare Disease Franchise global medical strategies for five products and launched an extended half-life product in the US
Led global team (8 FTEs) based in EU and US
Interim Medical Director EMEA
Developed and executed EMEA medical strategies for Haematology rare disease Franchise
Led two regional PhIV studies and launched a PK device across Europe